Purpura Fulminans

What is Purpura Fulminans?

Purpura fulminans is a rare and severe blood clotting disorder. It causes sudden skin damage and bleeding problems throughout the body. The condition happens when small blood vessels form clots while bleeding occurs at the same time.

This disorder creates purple or black patches on the skin that can quickly spread. The affected skin tissue can die because blood cannot reach it properly. Purpura fulminans is a medical emergency that requires immediate hospital care.

The condition can develop in three ways. It may appear in newborns with inherited clotting protein deficiencies. It can follow severe infections in children and adults. It can also occur after certain bacterial or viral illnesses. Early recognition and treatment are critical for the best outcomes.

Protein S Antigen, Free

Checks blood clotting protein levels
Measures protein that prevents clots
Assesses risk of blood clots

^$781

Symptoms

Sudden appearance of purple, red, or black patches on the skin
Skin areas that feel painful, tender, or numb
Rapid spreading of dark skin lesions
Fever and chills, especially with infection-related cases
Low blood pressure and rapid heartbeat
Bleeding from multiple sites including gums, nose, or injection sites
Confusion or altered mental state
Reduced urine output
Tissue death or gangrene in affected areas
Shock symptoms including cold, clammy skin

Most people with purpura fulminans become very ill very quickly. Symptoms typically appear suddenly and worsen within hours. Newborns with the inherited form may show signs within days after birth.

Causes and risk factors

Purpura fulminans has three main causes. Congenital purpura fulminans occurs in babies born with severe deficiencies of clotting proteins like Protein C, Protein S, or antithrombin. Acute infectious purpura fulminans follows severe bacterial infections, particularly meningococcal disease or streptococcal infections. Post-infectious purpura fulminans can develop 7 to 10 days after infections like chickenpox or scarlet fever.

Risk factors include family history of blood clotting disorders, severe bacterial infections, recent viral illnesses, and being a newborn or young child. People with weakened immune systems face higher risk. Those who have had their spleen removed are also more vulnerable. Certain genetic mutations affect how the body makes clotting proteins, increasing risk for the inherited form.

How it's diagnosed

Doctors diagnose purpura fulminans based on physical symptoms and specialized blood tests. The distinctive skin lesions combined with signs of bleeding and clotting help identify the condition quickly. Blood tests measure clotting factors, platelet counts, and proteins that control blood clotting.

Specialized testing checks levels of Protein C, Protein S, and other clotting factors. These tests help determine if the condition is inherited or acquired. Doctors may also perform blood cultures to identify infections. Imaging tests can assess organ damage. Because this is a rare and complex condition requiring specialized testing, talk to a doctor about appropriate diagnostic workup and monitoring.

Treatment options

Immediate hospitalization in an intensive care unit for close monitoring
Intravenous antibiotics if infection is present or suspected
Replacement of clotting proteins through fresh frozen plasma or protein concentrates
Anticoagulation therapy with heparin to prevent further clotting
Supportive care including fluids, blood pressure support, and oxygen
Surgical removal of dead tissue if necessary after stabilization
Long-term anticoagulation therapy for those with inherited forms
Skin grafting or reconstructive surgery for severe skin damage
Ongoing monitoring by hematology specialists
Genetic counseling for families affected by inherited forms

Frequently asked questions

Regular purpura causes purple spots from bleeding under the skin but is usually not life-threatening. Purpura fulminans is a severe emergency involving both widespread clotting and bleeding. It causes rapid tissue death and can affect multiple organs. Regular purpura may have many causes and often resolves on its own, while purpura fulminans requires immediate intensive care.

Purpura fulminans typically progresses very rapidly, often within hours. Skin lesions can appear and spread across large areas of the body in just a few hours. Tissue death can begin within 24 to 48 hours without treatment. The rapid progression makes this condition a true medical emergency requiring immediate hospital care.

Prevention depends on the type. Newborns with known family history of clotting disorders can be tested and treated early. Prompt treatment of severe infections may reduce risk of infection-related cases. Vaccination against meningococcal and pneumococcal bacteria helps prevent some triggering infections. People with inherited clotting disorders may need preventive anticoagulation therapy.

Survivors may face significant complications including limb amputation due to tissue death. Skin scarring and need for reconstructive surgery are common. Some people develop chronic kidney problems or neurological complications. Those with inherited forms require lifelong anticoagulation therapy and monitoring. Early treatment improves outcomes and reduces long-term complications.

Newborns with inherited deficiencies of Protein C, Protein S, or antithrombin face highest risk. Children and adults with severe bacterial infections, especially meningococcal disease, are vulnerable. People who have had their spleen removed have increased risk. Those with weakened immune systems or recent viral infections like chickenpox also face higher risk.

Purpura fulminans itself is not contagious. However, the infections that can trigger it may be contagious. Meningococcal disease and streptococcal infections can spread from person to person. People in close contact with someone who has these infections may need preventive antibiotics. The inherited form has no infectious component at all.

Blood tests measure levels and activity of Protein C, Protein S, and antithrombin. Genetic testing can identify specific mutations causing the deficiency. Testing is often done on newborns with family history of clotting disorders. Parents and siblings may also be tested to identify carriers. These specialized tests require specific laboratory capabilities and interpretation by hematology experts.

Yes, adults can develop purpura fulminans, usually after severe infections. The infection-related form most commonly follows bacterial infections like meningococcal disease. Adults with hidden inherited clotting disorders may show symptoms for the first time during severe illness or stress. Post-infectious purpura fulminans can occur after viral infections at any age.

Survival rates vary based on the type and how quickly treatment begins. With prompt intensive care, survival rates have improved significantly. The infection-related form has mortality rates of 20 to 50 percent depending on the triggering infection. Early recognition and aggressive treatment are the most important factors affecting survival. Access to specialized blood products and intensive care improves outcomes.

Meningococcemia is an infection caused by meningococcal bacteria. Purpura fulminans is a clotting disorder that can result from meningococcemia or other causes. Not everyone with meningococcemia develops purpura fulminans. Purpura fulminans can also occur from other infections or inherited clotting problems. Meningococcemia is the trigger, while purpura fulminans is the severe clotting complication.